Monopar Therapeutics Aktie

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Heres What You Should Know

The mean of analysts price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective,...

Monopar Therapeutics: Strong Data, But There Are Risks

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused...

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments...